Internal medicine, Sarcoma, Surgery, Chemotherapy and Oncology are his primary areas of study. His study ties his expertise on Osteosarcoma together with the subject of Internal medicine. His studies in Sarcoma integrate themes in fields like Cancer, Prospective cohort study and Survival analysis.
His research in Surgery intersects with topics in Gastroenterology and Primary tumor. His Chemotherapy research incorporates elements of Survival rate and Methotrexate. His Oncology study incorporates themes from Malignancy, Retrospective cohort study, Study groups, Large study and Histological response.
The scientist’s investigation covers issues in Internal medicine, Sarcoma, Surgery, Oncology and Osteosarcoma. His Gastroenterology research extends to the thematically linked field of Internal medicine. His Sarcoma study combines topics in areas such as Survival rate and Cancer.
His Surgery research includes themes of Primary tumor, Metastasis and Toxicity. In his study, Metastasectomy is inextricably linked to Lung, which falls within the broad field of Osteosarcoma. His Chemotherapy research is multidisciplinary, incorporating elements of Necrosis and Methotrexate.
Paul A. Meyers focuses on Internal medicine, Oncology, Sarcoma, Osteosarcoma and Cancer research. His work deals with themes such as Cancer, Clinical trial and Etoposide, Chemotherapy, Doxorubicin, which intersect with Oncology. His research on Chemotherapy concerns the broader Surgery.
His Sarcoma research entails a greater understanding of Pathology. His research in Osteosarcoma tackles topics such as Histological response which are related to areas like Study groups, Large study and Multivariate analysis. The various areas that Paul A. Meyers examines in his Cancer research study include Neuroendocrine tumors, Cell culture, Phase i study and Mutation.
His primary scientific interests are in Internal medicine, Osteosarcoma, Oncology, Chemotherapy and Ifosfamide. He studied Osteosarcoma and Young adult that intersect with Interquartile range, Confidence interval, Biopsy and Cohort. His biological study deals with issues like Clinical trial, which deal with fields such as Precision medicine and Immunohistochemistry.
His study with Chemotherapy involves better knowledge in Surgery. His Surgery research integrates issues from Neoadjuvant therapy, Primary tumor and Urology. His studies deal with areas such as Pediatrics, Sarcoma, Recursive partitioning and Doxorubicin as well as Etoposide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link.
The New England Journal of Medicine (2003)
Osteosarcoma treatment - where do we stand? A state of the art review.
Anja Luetke;Paul A. Meyers;Ian Lewis;Heribert Juergens.
Cancer Treatment Reviews (2014)
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
P A Meyers;G Heller;J Healey;A Huvos.
Journal of Clinical Oncology (1992)
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey.
Journal of Clinical Oncology (2008)
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman.
Journal of Clinical Oncology (2005)
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
P. A. Meyers;G. Heller;J. H. Healey;A. Huvos.
Journal of Clinical Oncology (1993)
Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway
Bang H. Hoang;Tadahiko Kubo;John H. Healey;Rui Yang.
Cancer Research (2004)
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino;Ayuko Hoshino;Han Sang Kim;Han Sang Kim;Linda Bojmar;Linda Bojmar;Linda Bojmar;Kofi Ennu Gyan.
R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
Alberto S. Pappo;Shreyaskumar R. Patel;John Crowley;Denise K. Reinke.
Journal of Clinical Oncology (2011)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina.
Journal of Clinical Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: